PharmaEssentia has built strong partnerships with a number of world-class collaborators ranging from university research institutes to biotechnology and pharmaceutical companies.
AOP Orphan is a multinational company with headquarters in Vienna, Austria focusing on clinical research, development and distribution of medicines for rare and complex diseases. The company also provides individualized and customized services to meet and accommodate the needs of physicians and patients across Central Europe, the Middle East & Asia. Currently AOP Orphan is concentrating on orphan and complex diseases in Hematology & Oncology, Cardiology & Pulmonology, and CNS & Gastroenterology.
Academia Sinica is the leading academic research institute in Taiwan. Beginning in 2003, PharmaEssentia has built a long-term partnership with this esteemed institute, and has been involved in collaborative studies in a range of projects including transgenic models of hepatitis B, biological material transfer, and process improvement of protein production.
Athenex is an innovative oncology company with drug discovery, drug formulation, clinical development, and API/drug product manufacturing facilities in both the U.S. and China.
PharmaEssentia has invested in clinical trials for hepatitis B and hepatitis C at the top hospitals in Taiwan, with these trials being executed by Dr. Ding-Shinn Chen, Dr. Yun-Fan Liaw, Dr. Pei-Jer Chen, Dr. Wan-Long Chuang and many other doctors.
(In an alphabetical order)